Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + gemcitabine + S-1 induction for cisplatin-intolerant locally advanced nasopharyngeal carcinoma
ChiCTR2600118783Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Incidence of grade ≥3 acute adverse events after induction therapy. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600118783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118783.